Antidepressant monotherapy for bipolar type II major depression
The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
Objectives: Bipolar type II (BP II) disorder is thought to be distinct from BP I disorder on genetic and biological grounds, and it is not merely a milder form of the illness. It affects 1.5–2.5% of the US adult population, and is characterized by highly recurrent depressive episodes with a substantial morbidity from alcoholism and non‐affective psychopathology, and a higher suicide rate than either BP I or unipolar depression. Treatment recommendations for BP II depression are based upon concerns over drug‐induced manic‐switch episodes, and suggest using either a mood stabilizer alone or a combination of an SSRI plus a mood stabilizer. Recent evidence, however, indicates that the rate of manic switch episodes may be modest in BP II patients. Recent studies have provided evidence that antidepressant monotherapy may be an effective initial and long‐term treatment for BP II major depression with a low manic‐switch rate. Methods: In this article, we review the recent literature on BP II disorder, with a focus on the treatment of BP II major depression. Results: We present a summary of data from recent studies by our group and others indicating that antidepressant monotherapy for BP II depression may be safe and effective with a low manic‐switch rate. Conclusion: Antidepressant monotherapy may be beneficial for some patients with BP II major depression.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Prien, R. F. (1984) · Archives of General Psychiatry · doi:10.1001/archpsyc.1983.01790220086014 · Cited by 565
Prien, R. F. (1973) · Archives of General Psychiatry · doi:10.1001/archpsyc.1973.04200030104017 · Cited by 448 · cited 1×
“(22) reported the presence of drug-induced mania in 67% of 44 BP I depressed patients taking imipramine, 12% of patients taking lithium, and 33% of patients taking placebo.”
BackgroundRapid Cycling in Manic-Depressives Induced by Tricyclic Antidepressants
Wehr, T. A. (1979) · Archives of General Psychiatry · doi:10.1001/archpsyc.1979.01780050065007 · Cited by 408 · cited 2×
“Wehr and Goodwin (24) reported accelerated 'cycling' during TCA treatment in five rapidly cycling, female BP I patients.”
BackgroundIs bipolar disorder still underdiagnosed? Are antidepressants overutilized?
Ghaemi, S. N., Sachs, G. S., M. Chiou, A., Pandurangi, A. K., & Goodwin, F. K. (1999) · Journal of Affective Disorders · doi:10.1016/s0165-0327(98)00076-7 · Cited by 376
Tranylcypromine versus imipramine in anergic bipolar depression
(1991) · American Journal of Psychiatry · doi:10.1176/ajp.148.7.910 · Cited by 360
A prospective follow-up of patients with bipolar and primary unipolar affective disorder
Winokur, G. (1993) · Archives of General Psychiatry · doi:10.1001/archpsyc.1993.01820180059006 · Cited by 249 · cited 1×
“BP II disorder is diagnostically stable over time (10-13) and rarely evolves into BP I (manic-depressive) disorder (12).”
BackgroundOutcome After Rapid vs Gradual Discontinuation of Lithium Treatment in Bipolar Disorders
Faedda, G. L. (1993) · Archives of General Psychiatry · doi:10.1001/archpsyc.1993.01820180046005 · Cited by 239 · cited 1×
“(28) found that 20 of 38 (53%) BP I patients, and none of 26 BP II patients developed a manic episode following lithium discontinuation.”
BackgroundEfficacy and Safety of Fluoxetine in Treating Bipolar II Major Depressive Episode
Amsterdam, J. D., Garcia-Espana, F., Fawcett, J., Quitkin, F. M., Reimherr, F. W., Rosenbaum, J. F., Schweizer, E., & Beasley, C. (1998) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199812000-00003 · Cited by 167 · cited 6×
“These observations comport well with more recent data from our group in BP II patients treated with fluoxetine (38) and venlafaxine (51, 58).”
BackgroundResultSelf-citation
Cited by
Grunze, H., Vieta, E., Goodwin, G. M., Bowden, C., Licht, R. W., Möller, H.-J., Kasper, S., & WFSBP Task Force On Treatment Guidelines For Bipolar Disorders (2010) · The World Journal of Biological Psychiatry · doi:10.3109/15622970903555881 · Cited by 399
Pramipexole for bipolar II depression: a placebo-controlled proof of concept study
Zarate, C. A., Payne, J. L., Singh, J., Quiroz, J. A., Luckenbaugh, D. A., Denicoff, K. D., Charney, D. S., & Manji, H. K. (2004) · Biological Psychiatry · doi:10.1016/j.biopsych.2004.03.013 · Cited by 347
Antidepressants in bipolar depression: An enduring controversy
Gitlin, M. J. (2018) · International Journal of Bipolar Disorders · doi:10.1186/s40345-018-0133-9 · Cited by 116
Bipolar depression: issues in diagnosis and treatment
Thase, M. E. (2005) · Harvard Review of Psychiatry · doi:10.1080/10673220500326425 · Cited by 89
Amsterdam, J. D., & Shults, J. (2005) · International Clinical Psychopharmacology · doi:10.1097/01.yic.0000171519.64080.c9 · Cited by 76
Self-citation
Metadata
- Authors
- Amsterdam, J. D., & Brunswick, D. J.
- Venue
- Bipolar Disorders
- Publisher
- Wiley
- Published
- 2003-11-25
- Volume
- 5
- Issue
- 6
- Pages
- 388-395
- ISSN
- 1398-5647 (ISSN-L)
- 1399-5618
- OpenAlex
- W2118962528
- Cited by
- 58
- References
- 8
- FWCI
- 3.31
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Antidepressant monotherapy for bipolar type II major depression. https://app.cochat.ai/papers/10.1046/j.1399-5618.2003.00066.x
- The paper
- Amsterdam, J. D., & Brunswick, D. J. (2003). Antidepressant monotherapy for bipolar type II major depression. Bipolar Disorders. https://doi.org/10.1046/j.1399-5618.2003.00066.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.